Ruxolitinib

Medical uses

In the United States and the European Union, ruxolitinib is indicated for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia-vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. It is also indicated for the treatment of adults with polycythaemia vera who are resistant to or intolerant of hydroxyurea. Ruxolitinib is also indicated for the treatment of steroid-refractory acute graft-versus-host disease in people who are twelve years of age and older, and for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in people twelve years of age and older. It is commonly given as an oral tablet.

In the United States, ruxolitinib cream is indicated for the topical treatment of mild to moderate atopic dermatitis and vitiligo. In the European Union, ruxolitinib cream is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Side effects

In myelofibrosis, the most common side effects include thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), neutropenia (low levels of neutrophils), urinary tract infections (infection of the kidney, renal pelvis, ureter, bladder or urethra), bleeding, bruising, weight gain, hypercholesterolaemia (high blood cholesterol levels), dizziness, headache and raised liver enzyme levels.

In polycythaemia vera, the most common side effects include anemia (low red blood cell counts) and thrombocytopenia (low blood platelet count), bleeding, bruising, hypercholesterolaemia (high blood cholesterol levels), hypertriglyceridemia (high blood fat levels), dizziness, raised liver enzyme levels and high blood pressure.

In acute graft-versus-host disease, the most common hematologic adverse reactions include anemia, thrombocytopenia, and neutropenia. The most common nonhematologic adverse reactions include infections and edema.

Immunologic side effects have included herpes zoster (shingles) and case reports of opportunistic infections. Other viruses, such as LCMV and HSV1, were shown to replicate better in presence of ruxolitinib, this effect was counteracted by host-directed antiviral, NMT-inhibitors such DDD85646, the analogue of IMP-1088. Metabolic side effects have included weight gain. Laboratory abnormalities have included alanine transaminase (ALT) abnormalities, aspartate transaminase (AST) abnormalities, and mildly elevated cholesterol levels.

Mechanism of action

Ruxolitinib is a Janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.

History

In March 2012, the phase III Controlled Myelofibrosis Study with Oral JAK Inhibitor-I (COMFORT-I) and COMFORT-II trials showed significant benefits by reducing spleen size and relieving debilitating symptoms.

Society and culture

Legal status

In November 2011, ruxolitinib was approved by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis based on results of the COMFORT-I and COMFORT-II Trials.

In 2014, it was approved in polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea, based on the RESPONSE trial.

In May 2019, the indication for ruxolitinib was expanded in the US to include steroid-refractory acute graft-versus-host disease. The indication was further expanded in the US in September 2021, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in people 12 years of age and older.

In September 2021, ruxolitinib cream (sold under the brand name Opzelura) was approved for medical use in the United States for the treatment of mild to moderate atopic dermatitis (AD). It is the first topical Janus kinase inhibitor approved in the United States.

In July 2022, ruxolitinib cream (sold under the brand name Opzelura) was approved for medical use in the United States for the treatment of vitiligo.

On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Opzelura, intended for the treatment of non-segmental vitiligo. The applicant for this medicinal product is Incyte Biosciences Distribution B.V.

Research

It is being investigated for plaque psoriasis, relapsed diffuse large B-cell lymphoma, peripheral T-cell lymphoma., and large granular lymphocyte leukemia.

In February 2016, a phase III trial for pancreatic cancer was terminated due to insufficient efficacy.

Eight weeks-treatment with ruxolitinib blunted senescent cell-mediated inhibition of adipogenesis and increased insulin sensitivity in 22-month-old mice.

As of September 2019, a clinical trial is in progress to evaluate "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors".

Opportunistic and acquired viral infection (such as herpes zoster, LCMV and HSV1) is a risk that requires pausing JAK inhibitors treatment, treating the infection, research in cell based assays this effect was counteracted by host-directed antiviral, NMT-inhibitors such DDD85646, the analogue of IMP-1088.

References

References

1. "JAKAVI (Novartis Pharmaceuticals Australia Pty LTD) | Therapeutic Goods Administration (TGA)".
2. (2022-05-27). "JAKAVI ruxolitinib (as phosphate) 5 mg tablet blister pack (198934)".
3. (22 October 2009). "Jakavi Product information".
4. (5 April 2022). "Jakavi 10mg Tablets - Summary of Product Characteristics (SmPC)".
5. "Opzelura- ruxolitinib cream".
6. (20 April 2023). "Opzelura EPAR".
7. "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". WebMD.
8. (February 2012). "Ruxolitinib". Nature Reviews. Drug Discovery.
9. (October 2013). "Practical management of patients with myelofibrosis receiving ruxolitinib". Expert Review of Hematology.
10. (26 February 2020). "Jakafi- ruxolitinib tablet".
11. (January 2015). "Ruxolitinib versus standard therapy for the treatment of polycythemia vera". The New England Journal of Medicine.
12. (4 December 2014). "FDA Approves Jakafi® (Ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera".
13. (19 July 2022). "FDA approves topical treatment".
14. (August 2024). "Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate". Acta Crystallographica Section C.
15. (22 September 2021). "FDA approves ruxolitinib for chronic graft-versus-host disease".
16. (5 May 2022). "EU Commission Approval". Novartis.
17. (17 September 2018). "Jakavi EPAR".
18. (May 2013). "An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor". Chest.
19. (October 2025). "N-myristoyltransferase inhibitors as candidate broad-spectrum antivirals to treat viral infections promoted by immunosuppression associated with JAK inhibitors therapy". Antiviral Research.
20. (June 2010). "Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis". IDrugs.
21. (March 2011). "Targeting myeloproliferative neoplasms with JAK inhibitors". Current Opinion in Hematology.
22. (March 2012). "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis". The New England Journal of Medicine.
23. (March 2012). "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis". The New England Journal of Medicine.
24. (March 2012). "Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms". The New England Journal of Medicine.
25. ASCO Annual Meeting 2011: [http://chicago2011.asco.org/ASCODailyNews/comfort.aspx JAK Inhibitor Ruxolitinib Demonstrates Significant Clinical Benefit in Myelofibrosis] {{webarchive. link. (21 November 2011)
26. "Drug Approval Package: Jakafi (ruxolitinib) Tablets NDA # 202192".
27. "FDA Approves Incyte's Jakafi (ruxolitinib) for Patients with Myelofibrosis". Incyte.
28. (4 December 2014). "Supplemental FDA approval letter for Jakafi (ruxolitinib) tablets". U.S. Food and Drug Administration.
29. (24 May 2019). "FDA approves ruxolitinib for acute graft-versus-host disease".
30. (31 January 2022). "FDA approves ruxolitinib for chronic graft-versus-host disease".
31. "Drug Approval Package: OPZELURA".
32. (21 September 2021). "Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)". Incyte.
33. (19 July 2022). "Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo". Incyte.
34. (24 February 2023). "Opzelura: Pending EC decision". [[European Medicines Agency]] (EMA).
35. (December 2014). "Emerging treatments in alopecia". Expert Opinion on Emerging Drugs.
36. {{ClinicalTrialsGov. NCT01431209. Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
37. (February 2016). "Incyte bags late-stage development of Jakafi for solid tumors; shares down 10% premarket.". Seeking Alpha.
38. (December 2015). "Targeting senescent cells enhances adipogenesis and metabolic function in old age". eLife.
39. {{ClinicalTrialsGov. NCT03610971. Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors